Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Ischemia 1Hemorrhage 1Blood Loss, Surgical 1

Interventions

Prednisone 103enzalutamide 76Docetaxel 73Abiraterone Acetate 68Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 39apalutamide 29Prednisolone 27bicalutamide 26Zoledronic Acid 24darolutamide 23radium Ra 223 dichloride 22pembrolizumab 22Goserelin 22Triptorelin Pamoate 17cabazitaxel 16Androgen Antagonists 15sipuleucel-T 13Injections 13luprolide acetate gel depot 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Cyclophosphamide 10Pluvicto 9Ipilimumab 9Dutasteride 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × maleimide-polyethylene glycol-modified hemoglobin, MP4 × Clear all
NCT00425334 2013-08-19

Safety Study of HemospanĀ® in Prostatectomy Patients

Sangart

Phase 2 Completed
20 enrolled
Genitourinary

Hemorrhage, Ischemia, Prostatic Neoplasms, Blood Loss, Surgical

Data powered by HemOnc (CC BY 4.0) Colophon ⚔